Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1CNS 1

Conditions

Brain Neoplasms 3Gliosarcoma 1Glioma 1Glioblastoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Carboplatin 366Pemetrexed 308pembrolizumab 301Cisplatin 241Paclitaxel 230Docetaxel 199Gemcitabine 130Nivolumab 121Erlotinib Hydrochloride 114Bevacizumab 85osimertinib 77atezolizumab 65durvalumab 58Cetuximab 57130-nm albumin-bound paclitaxel 56Gefitinib 52Ipilimumab 46Afatinib 38Drug Therapy 33Cyclophosphamide 30Crizotinib 30Albumin-Bound Paclitaxel 30Vinorelbine 28cemiplimab 26tislelizumab 25avelumab 23icotinib 22Radiotherapy 22capmatinib 21Oxaliplatin 21

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Carcinoma, Non-Small-Cell Lung × Spermine Synthase × Clear all
NCT03754530 2018-11-27

Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation

Betta Pharmaceuticals Co., Ltd.

Phase 2 Unknown
162 enrolled
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡